The post-finasteride syndrome: possible etiological mechanisms and symptoms

1. Access data. https://www.fda.gov/drugs/information-drug-class/5-alpha-reductase-inhibitor-information. Assessed 18 April 2023.

2. Cather JC, Lane D, Heaphy MR, Nelson BR. Finasteride—an update and review. Cutis. 1999;64:167–72. https://pubmed.ncbi.nlm.nih.gov/10500917/.

3. Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR. et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology. 2006;68:804–9. https://pubmed.ncbi.nlm.nih.gov/17070357/.

   PubMed 

   Google Scholar 

4. Severi G, Sinclair R, Hopper JL, English DR, McCredie MRE, Boyle P. et al. Androgenetic alopecia in men aged 40–69 years: prevalence and risk factors. Br J Dermatol. 2003;149:1207–13. https://pubmed.ncbi.nlm.nih.gov/14674898/.

   CAS 
   PubMed 

   Google Scholar 

5. Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab. 1996;81:814–9. https://pubmed.ncbi.nlm.nih.gov/8636309/.

   CAS 
   PubMed 

   Google Scholar 

6. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5α-reductase inhibitors for the enlarged prostate. Clin Ther. 2007;29:17–25. https://pubmed.ncbi.nlm.nih.gov/17379044/.

   CAS 
   PubMed 

   Google Scholar 

7. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Logan Holtgrewe H. et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338:557–63. https://pubmed.ncbi.nlm.nih.gov/9475762/.

   CAS 
   PubMed 

   Google Scholar 

8. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434–41. https://pubmed.ncbi.nlm.nih.gov/12350480/.

   PubMed 

   Google Scholar 

9. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault J-P, Afridi SK, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Can Med Assoc J. 1996;155:1251–9.

10. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123–31.

    CAS 
    PubMed 

    Google Scholar 

11. McClellan KJ, Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs. 1999;57:111–26. https://pubmed.ncbi.nlm.nih.gov/9951956/.

12. Cornu JN, Gacci M, Hashim H, Herrmann TRW, Malde S, Netsch C, et al. Non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO). EAU guidelines. Presented at the EAU Annual Congress Milan. The Netherlands; 2023.

13. Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016;82:128–34. http://www.ncbi.nlm.nih.gov/pubmed/26924401.

    PubMed 

    Google Scholar 

14. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8:1747–53. https://pubmed.ncbi.nlm.nih.gov/21418145/.

    PubMed 

    Google Scholar 

15. Kiguradze T, Temps WH, Yarnold PR, Cashy J, Brannigan RE, Nardone B, et al. Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride. PeerJ. 2017;5:e3020 https://doi.org/10.7717/peerj.3020.

16. Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M, et al. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017;5:671–8. https://pubmed.ncbi.nlm.nih.gov/28453908/.

17. Traish AM. Health risks associated with long-term finasteride and dutasteride use: it’s time to sound the alarm. World J Mens Health. 2020;38:323. https://pubmed.ncbi.nlm.nih.gov/32202088/.

    PubMed 
    PubMed Central 

    Google Scholar 

18. Diviccaro S, Melcangi RC, Giatti S. Post-finasteride syndrome: an emerging clinical problem. Neurobiol Stress. 2019;12:100209. https://pubmed.ncbi.nlm.nih.gov/32435662/.

19. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–24.

    CAS 
    PubMed 

    Google Scholar 

20. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F. et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202. https://pubmed.ncbi.nlm.nih.gov/20357281/.

    CAS 
    PubMed 

    Google Scholar 

21. Sarkar RR, Parsons JK, Bryant AK, Ryan ST, Kader AK, McKay RR, et al. Association of treatment with 5α-reductase inhibitors with time to diagnosis and mortality in prostate cancer. JAMA Intern Med. 2019;179:812–9.

    PubMed 
    PubMed Central 

    Google Scholar 

22. Yamana K, Fernand L, Luu-The V, Luu-The V. Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Investig. 2010;2:293–9. https://pubmed.ncbi.nlm.nih.gov/25961201/.

    CAS 
    PubMed 

    Google Scholar 

23. Wilson EM, French FS. Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. J Biol Chem. 1976;251:5620–9.

24. Siiteri PK, Wilson JD. Testosterone formation and metabolism during male sexual diflferentiation in the human embryo. J Clin Endocrinol Metab. 1974;38:113–25. https://pubmed.ncbi.nlm.nih.gov/4809636/.

    CAS 
    PubMed 

    Google Scholar 

25. Baldinotti F, Majore S, Fogli A, Marrocco G, Ghirri P, Vuerich M, et al. Molecular characterization of 6 unrelated Italian patients with 5α-reductase type 2 deficiency. J Androl. 2008;29:20–8.

    CAS 
    PubMed 

    Google Scholar 

26. MacLaughlin DT, Donahoe PK. Sex determination and differentiation. N Engl J Med. 2004;350:367–78. https://www.nejm.org/doi/10.1056/NEJMra022784.

27. Andriole G, Bruchovsky N, Chung LWK, Matsumoto AM, Rittmaster R, Roehrborn C. et al. Dihydrotestosterone and the prostate: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172:1399–403. https://pubmed.ncbi.nlm.nih.gov/15371854/.

    CAS 
    PubMed 

    Google Scholar 

28. Walsh PC, Madden JD, Harrod MJ, Goldstein JL, Macdonald PC, Wilson JD. Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 1974;291:944–9. https://pubmed.ncbi.nlm.nih.gov/4413434/.

    CAS 
    PubMed 

    Google Scholar 

29. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186:1213–5. https://pubmed.ncbi.nlm.nih.gov/4432067/.

    CAS 
    PubMed 

    Google Scholar 

30. Melcangi RC, Santi D, Spezzano R, Grimoldi M, Tabacchi T, Fusco ML, et al. Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. J Steroid Biochem Mol Biol. 2017;171:229–35.

    CAS 
    PubMed 

    Google Scholar 

31. Godoy A, Kawinski E, Li Y, Oka D, Alexiev B, Azzouni F. et al. 5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate. 2011;71:1033–46. https://onlinelibrary.wiley.com/doi/full/10.1002/pros.21318.

    CAS 
    PubMed 

    Google Scholar 

32. Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, et al. A new look at the 5α-reductase inhibitor finasteride. CNS Drug Rev. 2006;12:53–76. https://pubmed.ncbi.nlm.nih.gov/16834758/.

33. Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M. Adverse effects of 5α-reductase inhibitors: what do we know, don’t know, and need to know? Rev Endocr Metab Disord. 2015;16:177–98. https://pubmed.ncbi.nlm.nih.gov/26296373/.

34. Frye SV, Bramson HN, Hermann DJ, Lee FW, Sinhababu AK, Tian G. Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. Pharm Biotechnol Pharm Biotechnol. 1998;11:393–422. https://pubmed.ncbi.nlm.nih.gov/9760689/.

    CAS 
    PubMed 

    Google Scholar 

35. Roberts JL, Fiedler V, Imperato-McGinley J, Whiting D, Olsen E, Shupack J, et al. Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999;41:555–63.

    CAS 
    PubMed 

    Google Scholar 

36. Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology. 2008;72:808–12. https://pubmed.ncbi.nlm.nih.gov/18718641/.

    PubMed 

    Google Scholar 

37. Kligman AM. The comparative histopathology of male pattern baldness and senescent baldness. In: Clinics in Dermatology. Philadelphia: Lippincot. p. 2008;108–13.

38. Hoffmann R van. Recent findings with computerized methods for scalp hair growth measurements. J Investig Dermatol Symp Proc. 2005;10;285–8.

39. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W. et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39:578–89. https://pubmed.ncbi.nlm.nih.gov/9777765/.

    CAS 
    PubMed 

    Google Scholar 

40. Brenner S, Matz H. Improvement in androgenetic alopecia in 53-76-year-old men using oral finasteride. Int J Dermatol. 1999;38:928–30. https://pubmed.ncbi.nlm.nih.gov/10632776/.

    CAS 
    PubMed 

    Google Scholar 

41. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur J Endocrinol. 2001;145:669–79. https://pubmed.ncbi.nlm.nih.gov/11720889/.

    CAS 
    PubMed 

    Google Scholar 

42. Duskova M, Hill M, Hanuš M, Matoušková M, Stárka L. et al. Finasteride treatment and neuroactive steroid formation. Prague Med Rep. 2009;110:222–30. https://pubmed.ncbi.nlm.nih.gov/19655698/.

43. Melcangi RC, Caruso D, Abbiati F, Giatti S, Calabrese D, Piazza F, et al. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. J Sex Med. 2013;10:2598–603.

    CAS 
    PubMed 

    Google Scholar 

44. Caruso D, Abbiati F, Giatti S, Romano S, Fusco L, Cavaletti G, et al. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol. 2015;146:74–9. https://pubmed.ncbi.nlm.nih.gov/24717976/.

45. Li L, Kang YX, Ji XM, Li YK, Li SC, Zhang XJ. et al. Finasteride inhibited brain dopaminergic system and open-field behaviors in adolescent male rats. CNS Neurosci Ther. 2018;24:115–25. https://pubmed.ncbi.nlm.nih.gov/29214729/.

    CAS 
    PubMed 

    Google Scholar 

46. Roberto Frau R, Mosher LJ, Bini V, Pillolla G, Pes R, Saba P, et al. The neurosteroidogenic enzyme 5α-reductase modulates the role of D1 dopamine receptors in rat sensorimotor gating. Psychoneuroendocrinology. 2016;63:59–67. https://pubmed.ncbi.nlm.nih.gov/26415119/.

47. Bradshaw WG, Baum MJ, Awh CC. Attenuation by a 5α-reductase inhibitor of the activational effect of testosterone propionate on penile erections in castrated male rats. Endocrinology. 1981;109:1047–51. https://pubmed.ncbi.nlm.nih.gov/7285860/.

    CAS 
    PubMed 

    Google Scholar 

48. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8:872–84. http://www.ncbi.nlm.nih.gov/pubmed/21176115.

    CAS 
    PubMed 

    Google Scholar 

49. Moinpour CM, Darke AK, Donaldson GW, Thompson IM, Langley C, Ankerst DP. et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1025–35. https://pubmed.ncbi.nlm.nih.gov/17596576/.

    PubMed 

    Google Scholar 

50. Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73:1220–3. https://pubmed.ncbi.nlm.nih.gov/22939118/.

    CAS 
    PubMed 

    Google Scholar 

51. Jim Thornton. The Truth about Propecia. https://www.menshealth.com/health/a19531052/hair-raising-effect/ 18, 2011.

52. Post-Finasteride Syndrome Foundation. https://www.pfsfoundation.org/about-post-finasteride-syndrome-foundation/. Accessed 16 Jan 2023.

53. Healy D, Bahrick A, Bak M, Barbato A, Calabrò RS, Chubak BM, et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0). 66 D. Healy et al. / Diagnostic criteria for enduring sexual dysfunction after treatment. Int J Risk Saf Med. 2022;33:65–76.

    PubMed 
    PubMed Central 

    Google Scholar 

54. Pereira AFJR, Coelho TODA. Post-finasteride syndrome. Bras Dermatol. 2020;95:271–7.

    Google Scholar 

55. Belknap SM, Aslam I, Kiguradze T, Temps WH, Yarnold PR, Cashy J. et al. Adverse event reporting in clinical trials of finasteride for androgenic alopecia ameta-analysis. JAMA Dermatol. 2015;151:600–6. https://pubmed.ncbi.nlm.nih.gov/25830296/.

    PubMed 

    Google Scholar 

56. Favilla V, Russo GI, Privitera S, Castelli T, Giardina R, Calogero AE, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male. 2016;19:175–81. https://pubmed.ncbi.nlm.nih.gov/27310433/.

57. Hagberg KW, Divan HA, Persson R, Nickel JC, Jick SS. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. BMJ. 2016;354:i4823. https://pubmed.ncbi.nlm.nih.gov/27659058/.

    PubMed 

    Google Scholar 

58. Shin YS, Karna KK, Choi BR, Park JK. Finasteride and erectile dysfunction in patients with benign prostatic hyperplasia or male androgenic alopecia. World J Mens Health. 2019;37:157–65.

59. Nguyen DD, Herzog P, Cone EB, Labban M, Zorn KC, Chughtai B, et al. Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: a pharmacovigilance analysis of VigiBase. J Am Acad Dermatol. 2023;88:179–81. https://pubmed.ncbi.nlm.nih.gov/35351540/.

60. Nguyen DD, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N. et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 2021;157:35–42. https://jamanetwork.com/journals/jamadermatology/fullarticle/2772818.

    PubMed 

    Google Scholar 

61. Surendran P, Stewart ID, Yeung VPWA, Pietzner M, Raffler J, Wörheide MA, et al. Rare and common genetic determinants of metabolic individuality and their effects on human health. Nat Med. 2022;28:2321–32. https://doi.org/10.1038/s41591-022-02046-0.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

62. Baas WR, Butcher MJ, Lwin A, Holland B, Herberts M, Clemons J. et al. A review of the FAERS data on 5-alpha reductase inhibitors: implications for postfinasteride syndrome. Urology. 2018;120:143–9. https://pubmed.ncbi.nlm.nih.gov/29960004/.

    PubMed 

    Google Scholar 

63. Dowman JK, Hopkins LJ, Reynolds GM, Armstrong MJ, Nasiri M, Nikolaou N. et al. Loss of 5α-Reductase Type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology. 2013;154:4536–47. https://pubmed.ncbi.nlm.nih.gov/24080367/.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

64. Livingstone DEW, Barat P, Di Rollo EM, Rees GA, Weldin BA, Rog-Zielinska EA. et al. 5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents. Diabetes. 2015;64:447–58. https://pubmed.ncbi.nlm.nih.gov/25239636/.

    CAS 
    PubMed 

    Google Scholar 

65. Hazlehurst JM, Oprescu AI, Nikolaou N, Di Guida R, Grinbergs AEK, Davies NP. et al. Dual-5α-reductase inhibition promotes hepatic lipid accumulation in man. J Clin Endocrinol Metab. 2016;101:103–13. https://pubmed.ncbi.nlm.nih.gov/26574953/.

    CAS 
    PubMed 

    Google Scholar 

66. Upreti R, Hughes KA, Livingstone DEW, Gray CD, Minns FC, Macfarlane DP, et al. 5α-reductase type 1 modulates insulin sensitivity in men. J Clin Endocrinol Metab. 2014;99. https://pubmed.ncbi.nlm.nih.gov/24823464/.

67. Li K, Zhang C, Yang Z, Wang Y, Si H. Evaluation of a novel dry eye model induced by oral administration of finasteride. Mol Med Rep. 2017;16:8763–70. https://pubmed.ncbi.nlm.nih.gov/29039509/.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

68. Zhang C, Li K, Yang Z, Wang Y, Si H. The effect of the aqueous extract of Bidens pilosa L. on androgen deficiency dry eye in rats. Cell Physiol Biochem. 2016;39:266–77. https://pubmed.ncbi.nlm.nih.gov/27337217/.

    CAS 
    PubMed 

    Google Scholar 

69. Baig MS, Kolasa-Wołosiuk A, Pilutin A, Safranow K, Baranowska-Bosiacka I, Kabat-Koperska J, et al. Finasteride-induced inhibition of 5α-reductase type 2 could lead to kidney damage—animal, experimental study. Int J Environ Res Public Health. 2019;16. https://pubmed.ncbi.nlm.nih.gov/31100850/.

70. Mahony MC, Swanlund DJ, Billeter M, Roberts KP, Pryor JL. Regional distribution of 5α-reductase type 1 and type 2 mRNA along the human epididymis. Fertil Steril. 1998;69:1116–21.

    CAS 
    PubMed 

    Google Scholar 

71. Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ. et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92:1659–65. https://pubmed.ncbi.nlm.nih.gov/17299062/.

    CAS 
    PubMed 

    Google Scholar 

72. Chiba K, Yamaguchi K, Li F, Ando M, Fujisawa M. Finasteride-associated male infertility. Fertil Steril. 2011;95:1786.e9–1786.e11. http://www.fertstert.org/article/S0015028210029250/fulltext.

    PubMed 

    Google Scholar 

73. Irwig MS. Androgen levels and semen parameters among former users of finasteride with persistent sexual adverse effects. JAMA Dermatol Am Med Assoc. 2014;150:1361–3. https://pubmed.ncbi.nlm.nih.gov/25229565/.

    Google Scholar 

74. Samplaski MK, Lo K, Grober E, Jarvi K. Finasteride use in the male infertility population: effects on semen and hormone parameters. Fertil Steril. 2013;100:1542–6.

    CAS 
    PubMed 

    Google Scholar 

75. Traish AM. 5α-reductases in human physiology: an unfolding story. Endocr Pract Am Assoc Clin Endocrinol. 2012;18:965–75. https://pubmed.ncbi.nlm.nih.gov/23246684/.

    Google Scholar 

76. Bull HG. Mechanism-based inhibition of human steroid 5 alfa-reductase by finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J Am Chem Soc. 1996;118:2359–65.

    CAS 

    Google Scholar 

77. Giatti S, Foglio B, Romano S, Pesaresi M, Panzica G, Garcia-Segura LM. et al. Effects of subchronic finasteride treatment and withdrawal on neuroactive steroid levels and their receptors in the male rat brain. Neuroendocrinology. 2016;103:746–57. https://pubmed.ncbi.nlm.nih.gov/26646518/.

    CAS 
    PubMed 

    Google Scholar 

78. Römer B, Pfeiffer N, Lewicka S, Ben-Abdallah N, Vogt MA, Deuschle M. et al. Finasteride treatment inhibits adult hippocampal neurogenesis in male mice. Pharmacopsychiatry. 2010;43:174–8. https://pubmed.ncbi.nlm.nih.gov/20486040/.

    PubMed 

    Google Scholar 

79. Hercher C, Turecki G, Mechawar N. Through the looking glass: examining neuroanatomical evidence for cellular alterations in major depression. J Psychiatr Res. 2009;43:947–61. https://pubmed.ncbi.nlm.nih.gov/19233384/.

    PubMed 

    Google Scholar 

80. Diviccaro S, Giatti S, Borgo F, Barcella M, Borghi E, Trejo JL, et al. Treatment of male rats with finasteride, an inhibitor of 5alpha-reductase enzyme, induces long-lasting effects on depressive-like behavior, hippocampal neurogenesis, neuroinflammation and gut microbiota composition. Psychoneuroendocrinology. 2019;99:206–15. https://pubmed.ncbi.nlm.nih.gov/30265917/.

81. Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol. 2012;2012. http://blast.ncbi.nlm.nih.gov/Blast.cgi.

82. Da Silva MHA, Costa WS, Sampaio FJB, De Souza DB. The corpus cavernosum after treatment with dutasteride or finasteride: a histomorphometric study in a benign prostatic hyperplasia rodent model. Asian J Androl. 2018;20:505–10. https://pubmed.ncbi.nlm.nih.gov/29893293/.

    PubMed 
    PubMed Central 

    Google Scholar 

83. Lugg JA, Rajfer J, González-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology. 1995;136:1495–501. https://pubmed.ncbi.nlm.nih.gov/7534702/.

    CAS 
    PubMed 

    Google Scholar 

84. Zhang MG, Wang XJ, Shen ZJ, Gao PJ. Long-term oral administration of 5α-reductase inhibitor attenuates erectile function by inhibiting autophagy and promoting apoptosis of smooth muscle cells in corpus cavernosum of aged rats. Urology. 2013;82:743.e9–.e15. https://pubmed.ncbi.nlm.nih.gov/23876578/.

    PubMed 

    Google Scholar 

85. Kang HJ, Imperato-Mcginley J, Zhu YS, Rosenwaks Z. The effect of 5α-reductase-2 deficiency on human fertility. Fertil Steril. 2014;101:310–6. https://pubmed.ncbi.nlm.nih.gov/24412121/.

86. Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, et al. Finasteride 5 mg and sexual side effects: How many of these are related to a Nocebo phenomenon? J Sex Med. 2007;4:1708–12.

    PubMed 

    Google Scholar 

87. Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs. Drug Saf. 2014;37:283–94.

88. Irwig MS. Safety concerns regarding 5α reductase inhibitors for the treatment of androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes. 2015;22:248–53. https://pubmed.ncbi.nlm.nih.gov/25871957/.

    CAS 
    PubMed 

    Google Scholar 

89. Maksym RB, Kajdy A, Rabijewski M. Post-finasteride syndrome–does it really exist?. Aging Male. 2019;22:250–9. https://pubmed.ncbi.nlm.nih.gov/30651009/.

    PubMed 

    Google Scholar 

90. Healy D, Le Noury J, Mangin D. Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. Int J Risk Saf Med. 2018;29:125–34.

    PubMed 
    PubMed Central 

    Google Scholar 

91. Kastenmüller G, Raffler J, Gieger C, Suhre K. Genetics of human metabolism: an update. Hum Mol Genet. 2015. https://academic.oup.com/hmg/article/24/R1/R93/671706.

92. Howard DM, Adams MJ, Clarke T-K, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. http://www.nature.com/authors/editorial_policies/license.html#terms.

93. Ganzer CA, Jacobs AR. Emotional consequences of Finasteride: fool’s gold. Am J Mens Health. 2018;12:90–5. https://pubmed.ncbi.nlm.nih.gov/26868914/.

    PubMed 

    Google Scholar 

94. Irwig MS. Finasteride and suicide: a postmarketing case series. Dermatology. 2020;236:540–5. https://pubmed.ncbi.nlm.nih.gov/31935720/.

    CAS 
    PubMed 

    Google Scholar 

95. Fwu CW, Eggers PW, Kirkali Z, McVary KT, Burrows PK, Kusek JW. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J Urol. 2014;191:1828–34. https://pubmed.ncbi.nlm.nih.gov/24342143/.

96. Traish AM, Haider KS, Doros G, Haider A. Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. Horm Mol Biol Clin Investig. 2015;23:85–96. https://pubmed.ncbi.nlm.nih.gov/26053014/.

    CAS 
    PubMed 

    Google Scholar 

97. Liu L, Zhao S, Li F, Li E, Kang R, Luo L, et al. Effect of 5α-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Sex Med. 2016;13:1297–310. https://pubmed.ncbi.nlm.nih.gov/27475241/.

98. Roehrborn CG, Manyak MJ, Palacios-Moreno JM, Wilson TH, Roos EPM, Santos JC. et al. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 2018;121:647–58. https://pubmed.ncbi.nlm.nih.gov/29044968/.

    CAS 
    PubMed 

    Google Scholar 

99. Kosilov K, Kuzina I, Kuznetsov V, Gainullina Y, Kosilova L, Karashchuk E, et al. The risk of sexual dysfunction and effectiveness of treatment of benign prostatic hyperplasia with severe lower urinary tract dysfunction with combination of dutasteride and solifenacin. J Sex Med. https://doi.org/10.1016/j.jsxm.2018.09.011.

Download references